Cagrilintide 10mg
Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in
conjunction with insulin.
$ 168.00
Legal Notice:
THIS PRODUCT IS STRICTLY INTENDED FOR RESEARCH USE ONLY. It is designated solely as a research chemical. Usage is confined to in vitro testing and laboratory experimentation exclusively. Information available on our website about this product is for educational purposes only and should not be interpreted as an endorsement or directive for use outside these bounds. Introducing this product into humans or animals by any route is strictly prohibited by law. Handling of this product should be undertaken only by licensed, qualified professionals.
This product is not to be used as a drug, food, or cosmetic. Misbranding, misusing, or mislabeling this product as a drug, food, or cosmetic is illegal. Users are responsible for complying with all applicable laws and regulations regarding the handling and use of this product.
THIS PRODUCT IS STRICTLY INTENDED FOR RESEARCH USE ONLY. It is designated solely as a research chemical. Usage is confined to in vitro testing and laboratory experimentation exclusively. Information available on our website about this product is for educational purposes only and should not be interpreted as an endorsement or directive for use outside these bounds. Introducing this product into humans or animals by any route is strictly prohibited by law. Handling of this product should be undertaken only by licensed, qualified professionals.
This product is not to be used as a drug, food, or cosmetic. Misbranding, misusing, or mislabeling this product as a drug, food, or cosmetic is illegal. Users are responsible for complying with all applicable laws and regulations regarding the handling and use of this product.
Description
Cagrilintide is a long-acting analogue of amylin, a naturally occurring peptide that is released in
conjunction with insulin. Cagrilintide has shown promise in animal trials as a treatment for obesity
and type 2 diabetes. It has been studied for benefits not just in type 2 diabetes, but for liver
damage, alcohol-related liver disease, and heart/blood vessel disease. There is some
speculation about the role of this peptide in Alzheimer’s disease as well, but no research has
been published in that particular sub-domain, yet. Many trials, however, have looked at the
combination of cagrilintide and semaglutide in the treatment of obesity and type 2 diabetes. The
two proteins appear to work synergistically to provide more robust and more permanent weight
loss effects. It is important to note that while preclinical studies suggest promising therapeutic
potential, clinical trials in humans are limited. Further research needs to be done to determine the
efficacy and safety profiles.
Related products
